scholarly journals The diagnostic and prognostic value of UBE2T in intrahepatic cholangiocarcinoma

PeerJ ◽  
2020 ◽  
Vol 8 ◽  
pp. e8454
Author(s):  
Hua Yu ◽  
Han Wang ◽  
Wei Dong ◽  
Zhen-Ying Cao ◽  
Rong Li ◽  
...  
Keyword(s):  
Bile Duct ◽  
Confidence Interval ◽  
Intrahepatic Cholangiocarcinoma ◽  
Prognostic Value ◽  
Intrahepatic Bile Duct ◽  
Intraepithelial Neoplasia ◽  
Hazard Ratio ◽  
High Expression ◽  
Diagnostic Significance ◽  
Bile Duct Diseases

Background Ubiquitin-conjugating enzyme E2T (UBE2T) is overexpressed in several types of malignancies. However, little is known about its diagnostic significance in intrahepatic cholangiocarcinoma (ICC) and other bile duct diseases or its prognostic value in ICC. Methods The expression levels of UBE2T in the intrahepatic bile duct (IHBD, N = 13), biliary intraepithelial neoplasia (BilIN; BilIN-1/2, N = 23; BilIN-3, N = 11), and ICC (N = 401) were examined by immunohistochemistry. The differential diagnostic and prognostic values were also assessed. Results The number of UBE2T-positive cells was significantly higher in ICC tissues than in nonmalignant tissues, including the IHBD, BilIN-1/2, and BilIN-3 tissues. Kaplan–Meier analysis showed that overexpression of UBE2T was correlated with a shorter time to recurrence (TTR) and overall survival (OS). The 5-year TTR rates in the high UBE2T and low UBE2T groups were 100% and 86.2%, respectively. The corresponding OS rates were 1.9% and 22.2%, respectively. High expression of UBE2T was an independent risk factor for both TTR (hazard ratio: 1.345; 95% confidence interval: 1.047,1.728) and OS (hazard ratio: 1.420; 95% confidence interval: 1.098,1.837). Conclusions UBE2T can assist in differentiating benign bile duct diseases from ICC, and high expression of UBE2T suggests a poor prognosis for ICC.

scholarly journals Prognostic value of the miR-200 family in bladder cancer: a systematic review and meta-analysis

2020 ◽  
Author(s):  
Yanhui Mei ◽  
Jianbo Zheng ◽  
Ping Xiang ◽  
Cheng Liu ◽  
Yidong Fan
Keyword(s):  
Bladder Cancer ◽  
Confidence Interval ◽  
Publication Bias ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Hazard Ratio ◽  
High Expression ◽  
Cancer Specific Survival ◽  
Free Survival ◽  
Hazard Ratios

Abstract Introduction : The association between the miR-200 family and the prognosis of patients with bladder cancer remains controversial. The aim of this study is to evaluate the prognostic value of the miR-200 family in patients with bladder cancer.Methods : Electronic databases were searched to identify the studies that had assessed the association between the miR-200 family and prognosis in patients with bladder cancer. Hazard ratios ( HRs ) and 95% confidence interval ( CI ) for overall survival (OS), cancer-specific survival (CSS) and recurrence-free survival (RFS) from eligible studies were used to calculate combined hazard ratios. The heterogeneity across the included studies was assessed by Cochrane´s Q test and I 2 statistic. The Begg´s funnel plot and Egger´s linear regression teats were used to evaluate the potential publication bias. The meta-analysis was performed with RevMan 5.3 and Stata SE12.0 according to the PRISMA guidelines.Results : A total of 1152 patients from 8 studies were included in this meta-analysis. The results showed that the high expression of the miR-200 family was associated with better OS (pooled hazard ratio: 0.50, 95% confidence interval: 0.40-0.62), CSS (pooled hazard ratio: 0.36, 95% confidence interval: 0.22-0.59) and RFS (pooled hazard ratio: 0.48, 95% confidence interval: 0.36-0.65). Both Begg's funnel plots test and Egger's test verified that there was no publication bias within the included cohorts. Conclusion : This study suggests that the high expression of the miR-200 family is significantly associated with better prognosis in patients with bladder cancer.

scholarly journals Blood Pressure Variability, Mortality, and Cardiovascular Outcomes in CKD Patients

2019 ◽  
Vol 14 (2) ◽  
pp. 233-240 ◽  
Author(s):  
Francesca Mallamaci ◽  
Giovanni Tripepi ◽  
Graziella D’Arrigo ◽  
Silvio Borrelli ◽  
Carlo Garofalo ◽  
...  
Keyword(s):  
Confidence Interval ◽  
Cardiovascular Events ◽  
Prognostic Value ◽  
Clinic Visit ◽  
Hazard Ratio ◽  
Interquartile Range ◽  
Short Term ◽  
End Point

Background and objectivesShort-term BP variability (derived from 24-hour ambulatory BP monitoring) and long-term BP variability (from clinic visit to clinic visit) are directly related to risk for cardiovascular events, but these relationships have been scarcely investigated in patients with CKD, and their prognostic value in this population is unknown.Design, setting, participants, & measurementsIn a cohort of 402 patients with CKD, we assessed associations of short- and long-term systolic BP variability with a composite end point of death or cardiovascular event. Variability was defined as the standard deviation of observed BP measurements. We further tested the prognostic value of these parameters for risk discrimination and reclassification.ResultsMean ± SD short-term systolic BP variability was 12.6±3.3 mm Hg, and mean ± SD long-term systolic BP variability was 12.7±5.1 mm Hg. For short-term BP variability, 125 participants experienced the composite end point over a median follow-up of 4.8 years (interquartile range, 2.3–8.6 years). For long-term BP variability, 110 participants experienced the composite end point over a median follow-up of 3.2 years (interquartile range, 1.0–7.5 years). In adjusted analyses, long-term BP variability was significantly associated with the composite end point (hazard ratio, 1.24; 95% confidence interval, 1.01 to 1.51 per 5-mm Hg higher SD of office systolic BP), but short-term systolic BP variability was not (hazard ratio, 0.92; 95% confidence interval, 0.68 to 1.25 per 5-mm Hg higher SD of 24-hour ambulatory systolic BP). Neither estimate of BP variability improved risk discrimination or reclassification compared with a simple risk prediction model.ConclusionsIn patients with CKD, long-term but not short-term systolic BP variability is related to the risk of death and cardiovascular events. However, BP variability has a limited role for prediction in CKD.

scholarly journals Prognostic value of CD34 expression status in patients with myxofibrosarcomas and undifferentiated pleomorphic sarcomas

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Yoshiya Sugiura ◽  
Rikuo Machinami ◽  
Seiichi Matsumoto ◽  
Hiroaki Kanda ◽  
Keisuke Ae ◽  
...  
Keyword(s):  
Overall Survival ◽  
Prognostic Factor ◽  
Confidence Interval ◽  
Prognostic Value ◽  
Cox Model ◽  
Hazard Ratio ◽  
Rank Test ◽  
Log Rank Test ◽  
Cd34 Expression ◽  
Expression Status

AbstractIt is controversial whether patients with myxofibrosarcomas (MFSs) have better prognoses than those with undifferentiated pleomorphic sarcomas (UPSs). No useful prognostic factors have been established to date. We therefore aimed to evaluate the prognostic value of CD34 expression status in 192 patients with MFSs and UPSs. Using the log-rank test, we showed that patients with MFSs had a significantly better overall survival than did those with UPSs when defining the former as having a > 10% myxoid component (p = 0.03), but not when defining it as having a > 50% myxoid component (p = 0.1). Under the definition of MFSs as > 10% myxoid component, the log-rank test revealed that the diagnosis of the UPS and the CD34 loss (p < 0.001) were significant adverse predictors of overall survival. As per the Cox model, the CD34 loss remained an independent prognostic factor (hazard ratio = 3.327; 95% confidence interval 1.334–8.295), while the diagnosis of the UPS was a nonsignificant confounding factor (hazard ratio = 1.084; 95% confidence interval 0.679–1.727). In conclusion, CD34 expression status is a useful prognostic factor in patients with MFS and UPS, and it should be incorporated into grading systems that are used to predict outcomes.

scholarly journals Stress perfusion CMR provides strong long-term prognostic value to cardiac events irrespective of patient sex

2021 ◽  
Vol 22 (Supplement_1) ◽  
Author(s):  
T Pezel ◽  
F Sanguineti ◽  
M Kinnel ◽  
V Landon ◽  
P Garot ◽  
...  
Keyword(s):  
Confidence Interval ◽  
Prognostic Value ◽  
Cardiovascular Death ◽  
Hazard Ratio ◽  
Stress Perfusion ◽  
Inducible Ischemia ◽  
Stress Cmr ◽  
Perfusion Cmr

Abstract Funding Acknowledgements Type of funding sources: None. BACKGROUND    Compelling evidence indicates that women with coronary artery disease (CAD) experience worse outcomes than men due to a lack of early diagnosis and management. Numerous clinical studies have shown that stress cardiovascular magnetic resonance (CMR) detects evidence of myocardial ischemia and infarction at high accuracy. However, long-term prognosis data are limited.  PURPOSE The aim of this study was to test the hypothesis that stress perfusion CMR imaging can provide robust prognostic value in women presenting with suspected ischemia, to the same extent as in men.  METHODS   Consecutive patients referred for vasodilator stress perfusion CMR with dipyridamole were followed for the occurrence of major adverse cardiovascular events (MACE) defined as cardiovascular death or non-fatal myocardial infarction (MI). The secondary endpoint was cardiovascular death. The safety of the CMR was assessed by clinical monitoring for 1 hour after the end of the CMR. Univariable and multivariable Cox regressions for MACE were performed to determine the prognostic value of inducible ischemia or late gadolinium enhancement (LGE) by CMR in each sex.  RESULTS Of 3436 patients referred for stress CMR in a single French center, 3322 (97%) completed the CMR protocol (59.9 ± 11.8 years, 57% men), and among those 3033 (91%) completed the follow-up (median follow-up 5.4 ± 0.2 years). Reasons for failure to complete CMR included renal failure (n = 29), claustrophobia (n = 26), poor gating (n = 22), intolerance to stress agent (n = 19) and declining participation (n = 18).  Stress CMR was well tolerated without occurrence of death or severe disabling adverse event. Using Kaplan-Meier analysis, the presence of inducible myocardial ischemia identified the occurrence of MACE for both women (hazard ratio HR 2.36 ; 95% confidence interval CI: 1.54–3.62; p &lt; 0.001) and men (HR 3.57 ; 95% confidence interval CI: 2.75 – 4.64; p &lt; 0.001) (Figure). Moreover, inducible ischemia was associated with cardiovascular death for both women (hazard ratio HR 1.92; 95% confidence interval CI: 1.12 – 2.74; p = 0.04) and men (HR 2.71 ; 95% confidence interval CI: 1.98 – 4.41; p &lt; 0.001).  In a multivariable stepwise Cox regression including clinical characteristics and CMR, presence of inducible ischemia was an independent predictor of a higher incidence of MACE for both women (hazard ratio HR 1.85 ; 95% confidence interval CI: 1.18 – 2.92; p = 0.008) and men (HR 3.55 ; 95% confidence interval CI: 2.73 – 4.63; p &lt; 0.001). Moreover, inducible ischemia was associated with cardiovascular death for men (HR 1.99; 95% confidence interval CI: 1.65 – 3.01; p &lt; 0.01) but not for women (p = 0.11).  CONCLUSION Stress CMR is feasible, safe and has a good discriminative prognostic value to predict the occurrence of MACE in patients of either sex presenting with inducible ischemia. However, inducible ischemia is an independent predictor of a higher incidence of CV mortality only in men. Abstract Figure.

scholarly journals Benign Intrahepatic Bile Duct Stricture Difficult to Differentiate from an Intrahepatic Cholangiocarcinoma

2017 ◽  
Vol 50 (10) ◽  
pp. 803-811
Author(s):  
Takatsugu Yamamoto ◽  
Toru Miyazaki ◽  
Kazuhisa Kaneda ◽  
Masato Okawa ◽  
Shogo Tanaka ◽  
...  
Keyword(s):  
Bile Duct ◽  
Intrahepatic Cholangiocarcinoma ◽  
Intrahepatic Bile Duct ◽  
Bile Duct Stricture ◽  
Duct Stricture

scholarly journals Benign Intrahepatic Bile Duct Stricture Undiscriminated from Intrahepatic Cholangiocarcinoma

2013 ◽  
Vol 46 (1) ◽  
pp. 34-40 ◽  
Author(s):  
Ryuji Takahashi ◽  
Jinryo Takeda ◽  
Makoto Isobe ◽  
Maki Tanaka ◽  
Kohji Shinozaki ◽  
...  
Keyword(s):  
Bile Duct ◽  
Intrahepatic Cholangiocarcinoma ◽  
Intrahepatic Bile Duct ◽  
Bile Duct Stricture ◽  
Duct Stricture

scholarly journals Prognostic Value of mRNA Expression of MAP4K Family in Acute Myeloid Leukemia

2019 ◽  
Vol 18 ◽  
pp. 153303381987392 ◽  
Author(s):  
Zhenjie Bai ◽  
Qingmei Yao ◽  
Zhongyi Sun ◽  
Fang Xu ◽  
Jicheng Zhou
Keyword(s):  
Overall Survival ◽  
Acute Myeloid Leukemia ◽  
Confidence Interval ◽  
Myeloid Leukemia ◽  
Cox Regression ◽  
Hazard Ratio ◽  
Mitogen Activated Protein Kinase ◽  
High Expression ◽  
Low Expression ◽  
Acute Myeloid

Background: Despite diverse functions in diseases, the prognostic potential of the family of mitogen-activated protein kinase kinase kinase kinase genes in acute myeloid leukemia remains unknown. Methods: The messenger RNA expression of the MAP4K family members in 151 patients with acute myeloid leukemia was extracted from the OncoLnc database. Data for gender, age, cytogenetic, leukocyte count, CD34, FAB classification, RUNX1, and TP53 were provided by the University of California–Santa Cruz Xena platform. Kaplan-Meier analysis and Cox regression model provided an estimate of the hazard ratio with 95% confidence intervals for overall survival. Results: Analysis demonstrated favorable overall survival in patients with acute myeloid leukemia attributing to high expression of MAP4K3, MAP4K4, and MAP4K5 and low expression of MAP4K1 (adjusted P = .005, P = .022, P = .002, and P = .024; adjusted hazard ratio = 0.490, 95% confidence interval = 0.297-0.809, hazard ratio = 0.598, 95% confidence interval = 0.385-0.928, hazard ratio = 0.490, 95% confidence interval = 0.310-0.776, and hazard ratio = 0.615, 95% confidence interval = 0.403-0.938, respectively). Combining the high-expressing MAP4K3, MAP4K4, and MAP4K5 with the low-expressing MAP4K1 in a joint effect analysis predicted a favorable prognosis of overall survival in acute myeloid leukemia. Conclusion: High expression of MAP4K3, MAP4K4, and MAP4K5 combined with low expression of MAP4K1 can serve as a sensitive tool to predict favorable overall survival in patients with acute myeloid leukemia.

Sign in / Sign up

Export Citation Format

Share Document